Bharat Immunological Biological Corporation Ltd vs Ind Swift Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 16, 2026

Key Highlights

The Latest Trading Price of Bharat Immunological & Biological Corporation Ltd is ₹ 17.13 as of 16 Jun 15:30 . The P/E Ratio of Bharat Immunological & Biological Corporation Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Ind-Swift Laboratories Ltd changed from 6.9 on March 2023 to 2.3 on March 2025 . This represents a CAGR of -30.66% over 3 years The Market Cap of Bharat Immunological & Biological Corporation Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Ind-Swift Laboratories Ltd changed from ₹ 425.72 crore on March 2021 to ₹ 509.08 crore on March 2025 . This represents a CAGR of 3.64% over 5 years The revenue of Bharat Immunological & Biological Corporation Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Ind-Swift Laboratories Ltd for the Mar '26 is ₹ 172.01 crore as compare to the Dec '25 revenue of ₹ 178.43 crore. This represent the decline of -3.6% The ebitda of Bharat Immunological & Biological Corporation Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Ind-Swift Laboratories Ltd for the Mar '26 is ₹ 17.64 crore as compare to the Dec '25 ebitda of ₹ 25.9 crore. This represent the decline of -31.89% The net profit of Bharat Immunological & Biological Corporation Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Ind-Swift Laboratories Ltd changed from ₹ 1.01 crore to ₹ 15.11 crore over 8 quarters. This represents a CAGR of 286.79% The Dividend Payout of Bharat Immunological & Biological Corporation Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Ind-Swift Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Bharat Immunological & Biological Corporation Ltd

The Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science and Technology.
BIBCOL was incorporated in 1989.
The Company is engaged in the manufacture of Oral Polio Vaccine (OPV) , Zinc Tablets and Diarehha management Kit and BIB Sweet Tablets. The company's manufacturing unit is located in Bulandshahr Dist., Uttar Pradesh.
BIBCL installed a plant of 100 mln units.
Commercial production of the OPV started from Jan'96. The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme.

About Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Limited is a part of the Ind-Swift Group and is based at Chandigarh, Punjab, India.
The Company is one of the leading manufacturers of APIs catering to global and domestic formulators.
Based in Chandigarh, India, the Company operated two advanced manufacturing facilities in Derabassi and Jammu, adhering to international standards.
Ind-Swift Laboratories Ltd. is recognised globally as a leader in the Macrolide Antibiotic sector, and its products are well-regarded by major pharmaceutical formulators worldwide. Ind-Swift Laboratories Limited was incorporated on January 4, 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation.
Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company.

FAQs for the comparison of Bharat Immunological & Biological Corporation Ltd and Ind-Swift Laboratories Ltd

Which company has a larger market capitalization, Bharat Immunological & Biological Corporation Ltd or Ind-Swift Laboratories Ltd?

Market cap of Bharat Immunological & Biological Corporation Ltd is 74 Cr while Market cap of Ind-Swift Laboratories Ltd is 1,406 Cr

What are the key factors driving the stock performance of Bharat Immunological & Biological Corporation Ltd and Ind-Swift Laboratories Ltd?

The stock performance of Bharat Immunological & Biological Corporation Ltd and Ind-Swift Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bharat Immunological & Biological Corporation Ltd and Ind-Swift Laboratories Ltd?

As of June 16, 2026, the Bharat Immunological & Biological Corporation Ltd stock price is INR ₹17.14. On the other hand, Ind-Swift Laboratories Ltd stock price is INR ₹161.75.

How do dividend payouts of Bharat Immunological & Biological Corporation Ltd and Ind-Swift Laboratories Ltd compare?

To compare the dividend payouts of Bharat Immunological & Biological Corporation Ltd and Ind-Swift Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.